Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI
RESEARCH TOOLSreports
Holding ITCI?
Track your performance easily
ITCI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$45.50 - $84.89
Previous Close$74.72
Volume408.73K
Average Volume (3M)1.04M
Market Cap
$7.90B
Enterprise Value$6.89B
Total Cash (Recent Filing)$1.02B
Total Debt (Recent Filing)$18.29M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Nov 05, 2024EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding105,666,925
10 Day Avg. Volume522,662
30 Day Avg. Volume1,035,869
Standard Deviation0.35
R-Squared0.02
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)6.90
Price to Sales (P/S)13.80
Price to Cash Flow (P/CF)3585.30
P/FCF Ratio3973.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.18
Enterprise Value/Gross Profit16.08
Enterprise Value/Ebitda-113.37
Forecast
1Y Price Target
$96.43Price Target Upside28.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Intra-Cellular Therapies News
Bulls Say, Bears Say
Bulls Say
Pipeline And ApprovalsGiven the robustness of the Phase 3 trial data, Caplyta's approval in major depressive disorder is seen as a when, not if, and this could help drive an inflection on sales after launch.
Sales Force ExpansionITCI is ramping up the sales force by 150 to expand reach and frequency in primary care offices, setting up Caplyta for strong growth.
Sales GrowthStrong Caplyta sales growth continued, slightly above consensus, and keeping up with blockbuster expectations.
Bears Say
EarningsITCI traded down following earnings, likely due to the smaller-than-expected increase in Caplyta sales guidance and a lack of data readouts for the remainder of the year.
Investor ExpectationsThe hiring of a CFO will incrementally lower investor expectations around the potential of a near-term acquisition of ITCI.
Risk/RewardHigh investor expectations based on Study 501 topline results have skewed the risk/reward to the downside.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ITCI FAQ
What was Intra-Cellular Therapies’s price range in the past 12 months?
Intra-Cellular Therapies lowest stock price was $45.50 and its highest was $84.89 in the past 12 months.
What is Intra-Cellular Therapies’s market cap?
Currently, no data Available
When is Intra-Cellular Therapies’s upcoming earnings report date?
Intra-Cellular Therapies’s upcoming earnings report date is Nov 05, 2024 which is in 53 days.
How were Intra-Cellular Therapies’s earnings last quarter?
Intra-Cellular Therapies released its earnings results on Aug 07, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.03.
Is Intra-Cellular Therapies overvalued?
According to Wall Street analysts Intra-Cellular Therapies’s price is currently Undervalued.
Does Intra-Cellular Therapies pay dividends?
Intra-Cellular Therapies does not currently pay dividends.
What is Intra-Cellular Therapies’s EPS estimate?
Intra-Cellular Therapies’s EPS estimate is -$0.17.
How many shares outstanding does Intra-Cellular Therapies have?
Intra-Cellular Therapies has 105,666,920 shares outstanding.
What happened to Intra-Cellular Therapies’s price movement after its last earnings report?
Intra-Cellular Therapies reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -5.808%.
Which hedge fund is a major shareholder of Intra-Cellular Therapies?
Among the largest hedge funds holding Intra-Cellular Therapies’s share is Perceptive Advisors LLC. It holds Intra-Cellular Therapies’s shares valued at 118M.
---
Intra-Cellular Therapies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.43 (28.20% Upside)
$96.43 (28.20% Upside)
Blogger Sentiment
Bullish
ITCI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 652.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.33%
12-Months-Change
Fundamentals
Return on Equity
-9.63%
Trailing 12-Months
Asset Growth
85.05%
Trailing 12-Months
Company Description
Intra-Cellular Therapies
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
---
ITCI Earnings Call
Q2 2024
0:00 / 0:00
---
ITCI Stock 12 Month Forecast
Average Price Target
$96.43
▲(28.20% Upside)
Technical Analysis
Best Analysts Covering ITCI
1 Year
1 Year Success Rate
25/26 ratings generated profit
1 Year Average Return
+28.36%
reiterated a buy rating 2 months ago
Copying Andrew Tsai's trades and holding each position for 1 Year would result in 96.15% of your transactions generating a profit, with an average return of +28.36% per trade.
---